

# Patrick Legembre

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/789502/publications.pdf>

Version: 2024-02-01

84  
papers

5,681  
citations

159585  
30  
h-index

76900  
74  
g-index

94  
all docs

94  
docs citations

94  
times ranked

12224  
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. <i>Autophagy</i> , 2012, 8, 445-544.	9.1	3,122
2	CD95 ligand induces motility and invasiveness of apoptosis-resistant tumor cells. <i>EMBO Journal</i> , 2004, 23, 3175-3185.	7.8	291
3	Inhibition of IRE1 RNase activity modulates the tumor cell secretome and enhances response to chemotherapy. <i>Nature Communications</i> , 2018, 9, 3267.	12.8	192
4	Two CD95 tumor classes with different sensitivities to antitumor drugs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 11445-11450.	7.1	100
5	Induction of apoptosis and activation of NF- $\kappa$ B by CD95 require different signalling thresholds. <i>EMBO Reports</i> , 2004, 5, 1084-1089.	4.5	97
6	The Naturally Processed CD95L Elicits a c-Yes/Calcium/PI3K-Driven Cell Migration Pathway. <i>PLoS Biology</i> , 2011, 9, e1001090.	5.6	92
7	CD95L Cell Surface Cleavage Triggers a Prometastatic Signaling Pathway in Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2013, 73, 6711-6721.	0.9	91
8	S-Nitrosylation of the Death Receptor Fas Promotes Fas Ligand-Mediated Apoptosis in Cancer Cells. <i>Gastroenterology</i> , 2011, 140, 2009-2018.e4.	1.3	83
9	Downregulation of ceramide synthase-6 during epithelial-to-mesenchymal transition reduces plasma membrane fluidity and cancer cell motility. <i>Oncogene</i> , 2015, 34, 996-1005.	5.9	77
10	CD95-Mediated Calcium Signaling Promotes T Helper 17 Trafficking to Inflamed Organs in Lupus-Prone Mice. <i>Immunity</i> , 2016, 45, 209-223.	14.3	73
11	TRAIL receptor gene editing unveils TRAIL-R1 as a master player of apoptosis induced by TRAIL and ER stress. <i>Oncotarget</i> , 2017, 8, 9974-9985.	1.8	68
12	CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases. <i>Frontiers in Immunology</i> , 2017, 8, 1216.	4.8	64
13	Cutting Edge: Modulation of Fas-Mediated Apoptosis by Lipid Rafts in T Lymphocytes. <i>Journal of Immunology</i> , 2006, 176, 716-720.	0.8	63
14	Identification of SNF1/AMP Kinase-related Kinase as an NF- $\kappa$ B-regulated Anti-apoptotic Kinase Involved in CD95-induced Motility and Invasiveness. <i>Journal of Biological Chemistry</i> , 2004, 279, 46742-46747.	3.4	61
15	Does CD95 have tumor promoting activities?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2005, 1755, 25-36.	7.4	56
16	Nonapoptotic functions of Fas/CD95 in the immune response. <i>FEBS Journal</i> , 2018, 285, 809-827.	4.7	56
17	CD95 triggers Orai1-mediated localized Ca <sup>2+</sup> entry, regulates recruitment of protein kinase C (PKC) $\beta$ 2, and prevents death-inducing signaling complex formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 19072-19077.	7.1	52
18	CD95-mediated cell signaling in cancer: mutations and post-translational modulations. <i>Cellular and Molecular Life Sciences</i> , 2012, 69, 1261-1277.	5.4	47

#	ARTICLE	IF	CITATIONS
19	Localization of Fas/CD95 into the Lipid Rafts on Down-Modulation of the Phosphatidylinositol 3-Kinase Signaling Pathway. <i>Molecular Cancer Research</i> , 2008, 6, 604-613.	3.4	45
20	Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. <i>European Journal of Cancer</i> , 2010, 46, 1445-1455.	2.8	45
21	The CD95/CD95L signaling pathway: A role in carcinogenesis. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1846, 130-141.	7.4	42
22	Flt3-ligand induces adhesion of haematopoietic progenitor cells via a very late antigen (VLA)-4- and VLA-5-dependent mechanism. <i>British Journal of Haematology</i> , 2003, 120, 782-786.	2.5	40
23	Amplification of Fas-Mediated Apoptosis in Type II Cells via Microdomain Recruitment. <i>Molecular and Cellular Biology</i> , 2005, 25, 6811-6820.	2.3	39
24	The relevance of NF- $\kappa$ B for CD95 Signaling in Tumor Cells. <i>Cell Cycle</i> , 2004, 3, 1235-1239.	2.6	36
25	The HA tag is cleaved and loses immunoreactivity during apoptosis. <i>Nature Methods</i> , 2007, 4, 107-108.	19.0	36
26	Review of PI3K/mTOR Inhibitors Entering Clinical Trials to Treat Triple Negative Breast Cancers. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 283-296.	1.6	35
27	The apoptotic members CD95, Bcl <sub>x</sub> L, and Bcl-2 cooperate to promote cell migration by inducing Ca <sup>2+</sup> flux from the endoplasmic reticulum to mitochondria. <i>Cell Death and Differentiation</i> , 2016, 23, 1702-1716.	11.2	35
28	The Immunosuppressor Mycophenolic Acid Kills Activated Lymphocytes by Inducing a Nonclassical Actin-Dependent Necrotic Signal. <i>Journal of Immunology</i> , 2008, 181, 7630-7638.	0.8	34
29	Staphylococcus aureus-Induced G2/M Phase Transition Delay in Host Epithelial Cells Increases Bacterial Infective Efficiency. <i>PLoS ONE</i> , 2013, 8, e63279.	2.5	33
30	A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells. <i>Journal of Medicinal Chemistry</i> , 2015, 58, 6559-6573.	6.4	33
31	CD95/Fas and metastatic disease: What does not kill you makes you stronger. <i>Seminars in Cancer Biology</i> , 2020, 60, 121-131.	9.6	31
32	Cutting Edge: SDS-Stable Fas Microaggregates: An Early Event of Fas Activation Occurring with Agonistic Anti-Fas Antibody but Not with Fas Ligand. <i>Journal of Immunology</i> , 2003, 171, 5659-5662.	0.8	30
33	Potential of Fas-mediated apoptosis by an engineered glycosylphosphatidylinositol-linked Fas. <i>Cell Death and Differentiation</i> , 2002, 9, 329-339.	11.2	28
34	CD95 Structure, Aggregation and Cell Signaling. <i>Frontiers in Cell and Developmental Biology</i> , 2020, 8, 314.	3.7	28
35	CD95 engagement mediates actin-independent and -dependent apoptotic signals. <i>Cell Death and Differentiation</i> , 2009, 16, 1654-1664.	11.2	26
36	Staphylococcus aureus induces DNA damage in host cell. <i>Scientific Reports</i> , 2019, 9, 7694.	3.3	26

#	ARTICLE	IF	CITATIONS
37	Rewinding the DISC. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2008, 56, 9-14.	2.3	25
38	Actin-independent exclusion of CD95 by PI3K/AKT signalling: Implications for apoptosis. <i>European Journal of Immunology</i> , 2011, 41, 2368-2378.	2.9	25
39	Disrupting the CD95-PLC $\beta$ 3 interaction prevents Th17-driven inflammation. <i>Nature Chemical Biology</i> , 2018, 14, 1079-1089.	8.0	23
40	The Necrotic Signal Induced by Mycophenolic Acid Overcomes Apoptosis-Resistance in Tumor Cells. <i>PLoS ONE</i> , 2009, 4, e5493.	2.5	22
41	Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. <i>Science Translational Medicine</i> , 2021, 13, eabi4994.	12.4	22
42	Dominant-Negative Fas Mutation Is Reversed by Down-expression of c-FLIP. <i>Cancer Research</i> , 2007, 67, 108-115.	0.9	17
43	The cleaved FAS ligand activates the Na <sup>+</sup> /H <sup>+</sup> exchanger NHE1 through Akt/ROCK1 to stimulate cell motility. <i>Scientific Reports</i> , 2016, 6, 28008.	3.3	17
44	Cyaneodimycin, a Bioactive Compound Isolated from the Culture of <i>Streptomyces cyaneofuscatus</i> Associated with <i>Lichina confinis</i> . <i>European Journal of Organic Chemistry</i> , 2016, 2016, 3977-3982.	2.4	17
45	Precise Mapping of the CD95 Pre-Ligand Assembly Domain. <i>PLoS ONE</i> , 2012, 7, e46236.	2.5	16
46	Sphingolipids modulate the epithelial-mesenchymal transition in cancer. <i>Cell Death Discovery</i> , 2015, 1, 15001.	4.7	16
47	CD95/Fas suppresses NF- $\kappa$ B activation through recruitment of KPC2 in a CD95L/FasL-independent mechanism. <i>IScience</i> , 2021, 24, 103538.	4.1	16
48	Functional Characterization of a Chimeric Soluble Fas Ligand Polymer with In Vivo Anti-Tumor Activity. <i>PLoS ONE</i> , 2013, 8, e54000.	2.5	15
49	Redistribution of CD95 into the Lipid Rafts to Treat Cancer Cells?. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2010, 5, 22-28.	1.6	14
50	Serum CD95L Level Correlates with Tumor Immune Infiltration and Is a Positive Prognostic Marker for Advanced High-Grade Serous Ovarian Cancer. <i>Molecular Cancer Research</i> , 2019, 17, 2537-2548.	3.4	10
51	CD95/Fas protects triple negative breast cancer from anti-tumor activity of NK cells. <i>IScience</i> , 2021, 24, 103348.	4.1	10
52	Does calcium contribute to the CD95 signaling pathway?. <i>Anti-Cancer Drugs</i> , 2011, 22, 481-487.	1.4	9
53	The CD95 signaling pathway. <i>Communicative and Integrative Biology</i> , 2012, 5, 190-192.	1.4	9
54	Mycophenolic Acid Overcomes Imatinib and Nilotinib Resistance of Chronic Myeloid Leukemia Cells by Apoptosis or a Senescent-Like Cell Cycle Arrest. <i>Leukemia Research and Treatment</i> , 2012, 2012, 1-9.	2.0	9

#	ARTICLE	IF	CITATIONS
55	Chemical Composition, Antioxidant, and Anticancer Effect of <i>Ruta chalepensis</i> ™s Extracts against Human Leukemic Cells. <i>Phytotherapie</i> , 2018, 16, S225-S236.	0.1	9
56	Tumor analysis: freeze-thawing cycle of triple-negative breast cancer cells alters tumor CD24/CD44 profiles and the percentage of tumor-infiltrating immune cells. <i>BMC Research Notes</i> , 2018, 11, 401.	1.4	8
57	Identification of Agonistic and Antagonistic Antibodies against gp190, the Leukemia Inhibitory Factor Receptor, Reveals Distinct Roles for Its Two Cytokine-binding Domains. <i>Journal of Biological Chemistry</i> , 2001, 276, 47975-47981.	3.4	7
58	Soluble CD95L in cancers and chronic inflammatory disorders, a new therapeutic target?. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188596.	7.4	7
59	Fas/CD95 Signaling Pathway in Damage-Associated Molecular Pattern (DAMP)-Sensing Receptors. <i>Cells</i> , 2022, 11, 1438.	4.1	6
60	Investigation of Phospholipase C $\beta$ 1 Interaction with SLP76 Using Molecular Modeling Methods for Identifying Novel Inhibitors. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4721.	4.1	5
61	An insight into the role of the death receptor CD95 throughout pregnancy: Guardian, facilitator, or foe. <i>Birth Defects Research</i> , 2019, 111, 197-211.	1.5	5
62	Phospholipase A2 inhibitor and LY6/PLAUR domain-containing protein PINLYP regulates type I interferon innate immunity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	7.1	5
63	An atypical necrotic signal induced by immunosuppressive and anti-viral agents. <i>Autophagy</i> , 2009, 5, 425-427.	9.1	3
64	Study of the CD95-Mediated Non-apoptotic Signaling Pathway: PI3K. <i>Methods in Molecular Biology</i> , 2017, 1557, 103-110.	0.9	3
65	Single bilateral ovarian venous return in uterine transplant: Validation in an orthotopic auto-transplant model in the Yucatan minipig. <i>Journal of Gynecology Obstetrics and Human Reproduction</i> , 2021, 50, 102059.	1.3	3
66	Boyden Chamber Assay to Study of Cell Migration Induced by Metalloprotease Cleaved-CD95L. <i>Methods in Molecular Biology</i> , 2017, 1557, 117-123.	0.9	2
67	Editorial: Death Receptors, Non-apoptotic Signaling Pathways and Inflammation. <i>Frontiers in Immunology</i> , 2020, 11, 2162.	4.8	2
68	Keeping Cell Death Alive: An Introduction into the French Cell Death Research Network. <i>Biomolecules</i> , 2022, 12, 901.	4.0	2
69	CD95 Stimulation with CD95L and DISC Analysis. <i>Methods in Molecular Biology</i> , 2017, 1557, 11-18.	0.9	1
70	Proximity Ligation Assay (PLA) to Evaluate DISC and MISC Composition. <i>Methods in Molecular Biology</i> , 2017, 1557, 41-48.	0.9	1
71	Composition chimique, activité antioxydante et anticancéreuse des extraits de <i>Ruta chalepensis</i> sur des lignées de cellules leucémiques humaines. <i>Phytotherapie</i> , 0, , 1.	0.1	1
72	Synthesis of peptidomimetics and chemo-biological tools for CD95/PLC $\beta$ 1 interaction analysis. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 2094-2099.	2.2	1

#	ARTICLE	IF	CITATIONS
73	Probing the side chain tolerance for inhibitors of the CD95/PLC $\beta$ 1 interaction. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126669.	2.2	1
74	Myeloid-derived suppressor cell, arginase-1, IL-17 and cl-CD95L: an explosive cocktail in lupus?. <i>Annals of Translational Medicine</i> , 2016, 4, 554-554.	1.7	1
75	Chemotherapy with ceramide in TNBC. <i>Oncoscience</i> , 2015, 2, 817-818.	2.2	1
76	The CD95/CD95L Signaling Pathway: A Role in Carcinogenesis. , 2020, , 171-188.		1
77	R9: Potentialisation de la r�ponse apoptotique au Rituximab (RTX) dans les lymphomes B non hodgkinien : r�le du calcium. <i>Bulletin Du Cancer</i> , 2010, 97, S20.	1.6	0
78	Editorial [Hot topic: Stresses, Death Receptors and Plasma Membrane (Guest Editors: Patrick Legembre) Tj ETQq0 Q0 rgBT /Qverlock 10	1.8	0
79	T cell landscape in triple negative breast cancer patients. <i>Breast</i> , 2017, 32, S99.	2.2	0
80	FAS (Fas cell surface death receptor). <i>Atlas of Genetics and Cytogenetics in Oncology and Haematology</i> , 2017, , .	0.1	0
81	HIV protease inhibitors and autoimmunity: An odd, but promising idea. <i>Autoimmunity Reviews</i> , 2019, 18, 102370.	5.8	0
82	Atypical Immune Functions of CD95/CD95L. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2017, , 131-157.	0.1	0
83	Ovarian Cancer Immunity. , 2018, , .		0
84	Cleaved CD95L perturbs in vitro macrophages responses to <i>Toxoplasma gondii</i> . <i>Microbes and Infection</i> , 2022, , 104952.	1.9	0